Tempest Therapeutics (NASDAQ:TPST) Issues Quarterly Earnings Results

Tempest Therapeutics (NASDAQ:TPST) issued its quarterly earnings data on Thursday. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04), FiscalAI reports.

Tempest Therapeutics Stock Down 13.2%

Shares of Tempest Therapeutics stock opened at $1.01 on Friday. The business has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.70. Tempest Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $12.23. The firm has a market cap of $16.22 million, a P/E ratio of -0.24 and a beta of -1.72.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned approximately 0.23% of Tempest Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Wall Street Analysts Forecast Growth

TPST has been the topic of several analyst reports. Zacks Research downgraded Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.